No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam

Eur J Clin Pharmacol. 2008 Oct;64(10):1033-5. doi: 10.1007/s00228-008-0503-9. Epub 2008 Jun 28.

Authors

D Tomalik-Scharte, O Doroshyenko, J Kirchheiner, A Jetter, A Lazar, T Klaassen, D Frank, C Wyen, G Fätkenheuer, U Fuhr

PMID: 18587567
DOI: 10.1007/s00228-008-0503-9

No abstract available

Publication types

Letter

MeSH terms

Administration, Oral
Adult
Biological Availability
Case-Control Studies
Cytochrome P-450 CYP3A / genetics
Cytochrome P-450 CYP3A / metabolism*
Female
HIV Infections / blood
HIV Seropositivity / blood
Humans
Injections, Intravenous
Intestinal Mucosa / metabolism*
Liver / metabolism*
Male
Metabolic Clearance Rate
Midazolam / administration & dosage
Midazolam / blood
Midazolam / metabolism*
Midazolam / pharmacokinetics
Middle Aged
Polymorphism, Genetic

Substances

CYP3A5 protein, human
Cytochrome P-450 CYP3A
Midazolam